Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Avalo Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 34 | 36 | +2 |
| Shares | 8.26M | 7.84M | −412.0K (−5.0%) |
| Value | $66.1M | $39.1M | −$27.0M (−40.8%) |
New holders (4)
Institutions that held Avalo Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Investments, LP | 12,889 | $64.3K | 0.00% |
| Boothbay Fund Management, LLC | 11,321 | $56.5K | 0.00% |
| Quadrature Capital Ltd | 10,976 | $54.8K | 0.00% |
| Raymond James Financial Inc | 1 | $5 | 0.00% |
Sold out (2)
Institutions that held Avalo Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| HRT Financial LP | 10,289 | $82.0K |
| Royal Bank of Canada | 212 | $2.00K |